LIVE
BIIB
Biogen Inc. · Health Care - Biotechnology
$196.58
+3.16% this month
VERSUS
⟷
COMPARE
GILD
Gilead Sciences, Inc. · Health Care - Biotechnology
$123.76
-5.16% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BIIB
2
GILD
3
Comparison scoreboard
GILD LEADS 3/5AI Score
BIIB 28.5
GILD ✓41.3
1Y Return
BIIB ✓+55.33%
GILD +14.59%
Fwd P/E
BIIB ✓11.99
GILD 12.99
Target Up.
BIIB +10.29%
GILD ✓+25.46%
Op. Margin
BIIB 22.90%
GILD ✓39.28%
Metrics last refreshed: 6/20/2026
Quick take
BIIB vs GILD Stock Comparison: AI Score, Valuation, Performance and Upside
Both BIIB and GILD are large-cap biotechs with established specialty drug franchises facing varying degrees of competitive pressure and working to build next-generation growth drivers. Gilead has a more durable, highly cash-generative HIV franchise, while Biogen is navigating a more complex MS decline and Alzheimer's commercial uncertainty.
BIIB vs GILD compares two established large-cap biotechs — Biogen's neurology-focused franchise navigating MS decline and Alzheimer's opportunity, versus Gilead's stable HIV cash engine expanding into oncology.
Live analysis · updated 6/20/2026
GILD holds the edge across 3 of 5 key metrics in this comparison. BIIB leads on both 1-year return (+55.33%) and forward P/E (11.99x vs 12.99x for GILD), a relatively favorable combination of momentum and valuation. GILD leads on both revenue growth (4.40%) and operating margin (39.28%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for GILD (+25.46%) than for BIIB (+10.29%).
Normalized 1Y performance
BIIB
GILD
Recent returns
BIIB
GILD
Analyst price targets & sentiment
BIIB · 31 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.2/5.0)
Price target range
analyst low$115.00
analyst high$260.00
analyst mean$220.63
current price$196.58
+10.3% upside to analyst mean
GILD · 26 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.9/5.0)
Price target range
analyst low$92.00
analyst mean$157.57
current price$123.76
+25.5% upside to analyst mean
Who should consider this stock?
BIIB may suit investors who:
- →See potential value in Biogen's Alzheimer's franchise if Leqembi adoption accelerates
- →Believe the multiple sclerosis franchise provides adequate near-term cash generation
- →Are comfortable with higher execution uncertainty in exchange for Alzheimer's disease upside potential
GILD may suit investors who:
- →Want exposure to a stable, large-cap biotech with a durable HIV cash cow
- →Value Gilead's expanding oncology portfolio in breast cancer and CAR-T
- →Prefer a more predictable, income-generating biotech with a meaningful dividend
Performance & AI score
| Metric | BIIB | GILD |
|---|---|---|
| AI score | 28.5 | 41.3 |
| AI rank | #2417 | #967 |
| Latest close | $196.58 | $123.76 |
| 1M return | +3.16% | -5.16% |
| 6M return | +14.22% | +1.98% |
| 1Y return | +55.33% | +14.59% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BIIB | GILD |
|---|---|---|
| 1Y ago | $15.54K (+55.4%) started 2025-06-18 | $11.46K (+14.6%) started 2025-06-18 |
| 5Y ago | $5.16K (-48.4%) started 2021-06-21 | $25.04K (+150.4%) started 2021-06-21 |
| 10Y ago | $8.28K (-17.2%) started 2016-06-20 | $29.99K (+199.9%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BIIB | GILD |
|---|---|---|
| Market cap | $29.53B | $155.93B |
| Trailing P/E | 21.51 | 17.09 |
| Forward P/E | 11.99 | 12.99 |
| Price/Sales | 1.99 | 4.87 |
| EV/Revenue | 3.20 | 5.66 |
| Analyst target | $220.63 | $157.57 |
| Target upside | +10.29% | +25.46% |
Growth, profitability & risk
| Metric | BIIB | GILD |
|---|---|---|
| Revenue growth | 1.90% | 4.40% |
| Earnings growth | 31.10% | 54.80% |
| EPS growth | +31.10% | +54.80% |
| FCF margin | +19.43% | +26.68% |
| Operating margin | 22.90% | 39.28% |
| Profit margin | 13.80% | 30.99% |
| ROIC proxy | 7.70% | 43.36% |
| Return on equity | 7.70% | 43.36% |
| Dividend yield | N/A | 2.61% |
| Beta | 0.18 | 0.33 |
| Debt/equity | 35.18 | 94.64 |
| Current ratio | 3.06 | 1.97 |
| Quick ratio | 2.02 | 1.54 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BIIB max drawdown14.34%
GILD max drawdown22.03%
BIIB max wkly drop12.37%
GILD max wkly drop5.98%
5Y risk snapshot
BIIB max drawdown70.23%
GILD max drawdown26.59%
BIIB max wkly drop13.62%
GILD max wkly drop9.78%
10Y risk snapshot
BIIB max drawdown72.66%
GILD max drawdown30.47%
BIIB max wkly drop34.30%
GILD max wkly drop12.29%
Performance metrics by period
| Period | Metric | BIIB | GILD |
|---|---|---|---|
| 1Y | Growth | +55.35% | +14.59% |
| CAGR | +55.45% | +14.61% | |
| Sharpe ratio | 1.36 | 0.48 | |
| Max drawdown | 14.34% | 22.03% | |
| Max daily drop | 6.43% | 4.28% | |
| Max wkly drop | 12.37% | 5.98% | |
| 5Y | Growth | -48.39% | +113.43% |
| CAGR | -12.41% | +16.40% | |
| Sharpe ratio | -0.36 | 0.56 | |
| Max drawdown | 70.23% | 26.59% | |
| Max daily drop | 7.39% | 10.15% | |
| Max wkly drop | 13.62% | 9.78% | |
| 10Y | Growth | -17.19% | +105.64% |
| CAGR | -1.87% | +7.48% | |
| Sharpe ratio | 0.04 | 0.23 | |
| Max drawdown | 72.66% | 30.47% | |
| Max daily drop | 29.23% | 10.15% | |
| Max wkly drop | 34.30% | 12.29% |
Business comparison
| Category | BIIB | GILD |
|---|---|---|
| Company | Biogen Inc. | Gilead Sciences, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Biogen is a large-cap biotechnology company focused on neurological diseases, including its established multiple sclerosis franchise (Tecfidera, Tysabri, Avonex) and its controversial Alzheimer's disease drugs (Aduhelm, Leqembi) developed in partnership with Eisai. | Gilead Sciences is a large-cap biotechnology company known for its dominant HIV antiretroviral franchise (Biktarvy, Descovy) and oncology portfolio (Trodelvy, Yescarta), with ongoing efforts to expand in viral hepatitis, inflammation, and other areas. |
| Investor focus | Investors track Leqembi adoption for Alzheimer's disease, Biogen's multiple sclerosis franchise durability against biosimilar and competitive pressure, and the overall pipeline strategy to offset declining MS revenues. | Investors track Biktarvy's HIV market leadership, Trodelvy's expansion in breast cancer and beyond, Yescarta's performance in CAR-T therapy, and Gilead's business development pipeline to supplement internal R&D. |
BIIB strengths
- →Established leader in multiple sclerosis with a broad portfolio of FDA-approved therapies
- →Leqembi (lecanemab) represents a potential franchise in Alzheimer's if it achieves meaningful commercial adoption
- →Strong balance sheet and free cash flow provides flexibility for acquisitions and pipeline investment
GILD strengths
- →Biktarvy is the leading HIV treatment with a large, stable, recurring revenue base from patients on long-term therapy
- →Oncology portfolio through Trodelvy (breast cancer) and Yescarta (CAR-T) provides diversification beyond HIV
- →Strong cash flow from HIV franchise funds acquisitions and pipeline investment
Risks to watch — BIIB
- →MS franchise faces biosimilar competition and revenue pressure as key drugs lose exclusivity
- →Leqembi has seen slow initial commercial adoption due to complex administration, safety monitoring, and payer access issues
- →Biogen has had a difficult period of strategic uncertainty following the controversial and then withdrawn Aduhelm Alzheimer's drug
Risks to watch — GILD
- →HIV franchise, while durable, faces eventual long-acting injectable competition and generics over time
- →Oncology products Trodelvy and Yescarta are growing but still represent a smaller share of revenue than HIV
- →Gilead has a mixed recent track record with its acquisitions relative to the prices paid
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →